MetaCap

Novartis (NVS) vs Pfizer (PFE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novartis (NVS) has outperformed Pfizer (PFE) over the past year, gaining 18.2% versus a gain of 9.4%. Over five years, NVS leads with a +86.5% price change compared with -49.3% for PFE. Novartis is the larger company by market cap ($284.18 billion vs $156.18 billion), about 1.8 times the size.

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 15.1x for Novartis). Pfizer offers the higher dividend yield (7.85% vs 3.10%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVS+18.19%PFE+9.42%
+34%+13%-7%
Nov 21, 20251 yearNov 20, 2026
NVS+84.26%PFE-46.06%
+115%+25%-65%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVS versus PFE key metrics
MetricNVSPFE
Share price$150.47$27.40
Market cap$284.18B$156.18B
1-day change-0.50%-0.51%
YTD return+9.14%+10.04%
1-year return+18.19%+9.42%
5-year return+86.46%-49.26%
P/E ratio (TTM)28.7239.14
Forward P/E15.159.28
EPS (TTM)$5.24$0.70
Dividend yield3.10%7.85%
Annual dividend$4.67$2.15
Revenue (latest FY)—$62.58B
Revenue growth (YoY)—-1.65%
Net income (latest FY)$13.98B$7.77B
Gross margin—74.33%
Net margin—12.42%
52-week high$170.46$31.44
52-week low$126.50$23.62
Distance from 52-week high-11.73%-12.85%
Analyst consensusholdbuy
Avg. price target upside+4.41%+10.29%
Average volume2.18M33.52M
Shares outstanding1.89B5.70B
Employees75,26775,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Pfizer trades at a higher earnings multiple (39.1x vs 28.7x trailing P/E).
  • Pfizer offers a meaningfully higher dividend yield (7.85% vs 3.10%).

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

NVS vs PFE FAQ

Which is bigger, Novartis or Pfizer?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $156.18B for Pfizer (PFE).

Which stock has performed better over the past year, NVS or PFE?

NVS returned +18.19% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVS or PFE?

NVS has the lower trailing P/E at 28.7, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novartis or Pfizer?

Pfizer has the higher yield at 7.85%, compared with 3.10% for Novartis.

Are Novartis and Pfizer in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons